A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides

Journal of the American Academy of Dermatology

Volumn 55, Issue 5, 2006, Pages 807-813

  Duvic, Madeleine ^a   Sherman, Matthew L ^b   Wood, Gary S ^c   Kuzel, Timothy M ^d   Olsen, Elise ^e   Foss, Francine ^f   Laliberté, Robert J ^b   Ryan, John L ^b   Zonno, Kristilyn ^b   Rook, Alain H ^g  

^a University of Texas Health Science Center   (United States)

^b PFIZER INC   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f YALE UNIVERSITY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; RECOMBINANT INTERLEUKIN 12;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; FEMALE; FOLLOW UP; HEMOLYTIC ANEMIA; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; LEUKOPENIA; MALE; MULTICENTER STUDY; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA; NECK PAIN; PAIN; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RATING SCALE; RHINITIS; SIDE EFFECT; SWEATING; XEROSTOMIA;

ADJUVANTS, IMMUNOLOGIC; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-12; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; RECOMBINANT PROTEINS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 33749684290     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.06.038     Document Type: Article

References (34)

1. Noble A., Thomas M.J., and Kemeny D.M. Early Th1/Th2 cell polarization in the absence of IL-4 and IL-12: T cell receptor signaling regulates the response to cytokines in CD4 and CD8 T cells. Eur J Immunol 31 (2001) 2227-2235
2. O'Garra A., and Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol 10 (2000) 542-550
3. Palmer E.M., and van Seventer G.A. Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell-dependent costimulatory signals. J Immunol 158 (1997) 2654-2662
4. Smits H.H., van Rietschoten J.G., Hilkens C.M., Sayilir R., Stiekema F., Kapsenberg M.L., et al. IL-12-induced reversal of human Th2 cells is accompanied by full restoration of IL-12 responsiveness and loss of GATA-3 expression. Eur J Immunol 31 (2001) 1055-1065
5. Sornasse T., Larenas P.V., Davis K.A., de Vries J.E., and Yssel H. Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T cells, analyzed at the single-cell level. J Exp Med 184 (1996) 473-483
6. Syrbe U., Siveke J., and Hamann A. Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression?. Springer Semin Immunopathol 21 (1999) 263-285
7. Trinchieri G. Pro-inflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 16 (1998) 365-396
8. Wesch D., Glatzel A., and Kabelitz D. Differentiation of resting human peripheral blood gamma delta T cells toward Th1- or Th2-phenotype. Cell Immunol 212 (2001) 110-117
9. Rook A.H., Gottlieb S.L., Wolfe J.T., Vowels B.R., Sood S.S., Niu Z., et al. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol 107 (1997) 16-20
10. Showe L.C., Fox F.E., Williams D., Au K., Niu Z., and Rook A.H. Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. J Immunol 163 (1999) 4073-4079
11. Dorfman D.M., and Shahsafaei A. CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas. Hum Pathol 33 (2002) 330-334
12. Ferenczi K., Fuhlbrigge R.C., Pinkus J., Pinkus G.S., and Kupper T.S. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 119 (2002) 1405-1410
13. Kakinuma T., Sugaya M., Nakamura K., Kaneko F., Wakugawa M., Matsushima K., et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 48 (2003) 23-30
14. Kleinhans M., Tun-Kyi A., Gilliet M., Kadin M.E., Dummer R., Burg G., et al. Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Blood 101 (2003) 1487-1493
15. Asadullah K., Docke W.D., Haeussler A., Sterry W., and Volk H.D. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 107 (1996) 833-837
16. Rook A.H., Kubin M., Cassin M., Vonderheid E.C., Vowels B.R., Wolfe J.T., et al. IL-12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 154 (1995) 1491-1498
17. Vowels B.R., Lessin S.R., Cassin M., Jaworsky C., Benoit B., Wolfe J.T., et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 103 (1994) 669-673
18. Kim E.J., Hess S., Richardson S.K., Newton S., Showe L.C., Benoit B.M., et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115 (2005) 798-812
19. Galli G., Chantry D., Annunziato F., Romagnani P., Cosmi L., Lazzeri E., et al. Macrophage-derived chemokine production by activated human T cells in vitro and in vivo: preferential association with the production of type 2 cytokines. Eur J Immunol 30 (2000) 204-210
20. Echchakir H., Bagot M., Dorothee G., Martinvalet D., Le Gouvello S., Boumsell L., et al. Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 115 (2000) 74-80
21. Harwix S., Zachmann K., and Neumann C. T-cell clones from early-stage cutaneous T-cell lymphoma show no polarized Th-1 or Th-2 cytokine profile. Arch Dermatol Res 292 (2000) 1-8
22. Apisarnthanarax N., and Duvic M. Cutaneous T-cell lymphoma. New immunomodulators. Dermatol Clin 19 (2001) 737-748
23. Rook A.H., Wood G.S., Yoo E.K., Elenitsas R., Kao D.M., Sherman M.L., et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94 (1999) 902-908
24. Rook A.H., Zaki M.H., Wysocka M., Wood G.S., Duvic M., Showe L.C., et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci 941 (2001) 177-184
25. Schmid M.H., Bird P., Dummer R., Kempf W., and Burg G. Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept. Arch Dermatol 135 (1999) 1204-1208
26. Stevens S.R., Ke M.S., Parry E.J., Mark J., and Cooper K.D. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol 138 (2002) 42-48
27. Ni X., Hazarika P., Zhang C., Talpur R., and Duvic M. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?. Clin Cancer Res 7 (2001) 2682-2692
28. Atkins M.B., Robertson M.J., Gordon M., Lotze M.T., DeCoste M., DuBois J.S., et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3 (1997) 409-417
29. Gollob J.A., Mier J.W., Veenstra K., McDermott D.F., Clancy D., Clancy M., et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6 (2000) 1678-1692
30. Motzer R.J., Rakhit A., Schwartz L.H., Olencki T., Malone T.M., Sandstrom K., et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4 (1998) 1183-1191
31. Robertson M.J., Cameron C., Atkins M.B., Gordon M.S., Lotze M.T., Sherman M.L., et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 5 (1999) 9-16
32. Weiss G.R., O'Donnell M.A., Loughlin K., Zonno K., Laliberte R.J., and Sherman M.L. Phase I study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother 26 (2003) 343-348
33. Portielje J.E., Gratama J.W., van Ojik H.H., Stoter G., and Kruit W.H. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 52 (2003) 133-144
34. Peterson A.C., Harlin H., and Gajewski T.F. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21 (2003) 2342-2348